Panel: The Evolving BD&L Landscape: Capital, Competition & Dealmaking Across Pharma and Biotech

Session details:

• Capital discipline, regulatory pressure, and risk-sharing are redefining how deals get done with regulatory expectations increasingly shaping deal value and structure, not just risk tolerance 
• How BD&L teams are evolving decision-making frameworks to prioritize smarter, more defensible investments
• The rapid rise of more complex, structured deals—and what it takes to stay competitive